JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥12,793 | ¥8,569 | ¥7,192 | ¥9,223 |
| % Growth | 49.3% | 19.1% | -22% | – |
| Cost of Goods Sold | ¥2,005 | ¥2,395 | ¥4,374 | ¥2,677 |
| Gross Profit | ¥10,788 | ¥6,174 | ¥2,818 | ¥6,546 |
| % Margin | 84.3% | 72.1% | 39.2% | 71% |
| R&D Expenses | ¥4,487 | ¥3,348 | ¥5,506 | ¥3,349 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥3,354 | ¥3,470 | ¥3,256 | ¥3,212 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥7,841 | ¥6,818 | ¥8,762 | ¥6,561 |
| Operating Income | ¥2,947 | -¥644 | -¥5,944 | -¥60 |
| % Margin | 23% | -7.5% | -82.6% | -0.7% |
| Other Income/Exp. Net | ¥345 | -¥107 | -¥153 | ¥253 |
| Pre-Tax Income | ¥3,292 | -¥751 | -¥6,097 | ¥238 |
| Tax Expense | ¥1,013 | -¥180 | -¥1,879 | ¥36 |
| Net Income | ¥2,256 | -¥546 | -¥4,183 | ¥115 |
| % Margin | 17.6% | -6.4% | -58.2% | 1.2% |
| EPS | 18.51 | -4.48 | -33.8 | 0.93 |
| % Growth | 513.2% | 86.7% | -3,734.4% | – |
| EPS Diluted | 18.5 | -4.48 | -33.8 | 0.94 |
| Weighted Avg Shares Out | 122 | 122 | 124 | 123 |
| Weighted Avg Shares Out Dil | 122 | 122 | 124 | 122 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥29 | ¥9 | ¥22 | ¥23 |
| Interest Expense | ¥78 | ¥79 | ¥52 | ¥40 |
| Depreciation & Amortization | ¥721 | ¥738 | ¥868 | ¥799 |
| EBITDA | ¥4,088 | ¥67 | -¥5,179 | ¥739 |
| % Margin | 32% | 0.8% | -72% | 8% |